MX2016001087A - Volasertib en combinacion con azacitidina para el tratamiento de leucemia mieloide aguda y sindrome mielodisplasico. - Google Patents

Volasertib en combinacion con azacitidina para el tratamiento de leucemia mieloide aguda y sindrome mielodisplasico.

Info

Publication number
MX2016001087A
MX2016001087A MX2016001087A MX2016001087A MX2016001087A MX 2016001087 A MX2016001087 A MX 2016001087A MX 2016001087 A MX2016001087 A MX 2016001087A MX 2016001087 A MX2016001087 A MX 2016001087A MX 2016001087 A MX2016001087 A MX 2016001087A
Authority
MX
Mexico
Prior art keywords
volasertib
azacitidine
combination
myeloid leukemia
acute myeloid
Prior art date
Application number
MX2016001087A
Other languages
English (en)
Inventor
Tillmann Taube
Dorothea Rudolph
Maria Del Roser Calvo Verges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51228430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2016001087A publication Critical patent/MX2016001087A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de Volasertib o a su sal o su hidrato en combinación con Azacitidina o a su sal o su hidrato para el tratamiento de pacientes que sufren de leucemia mieloide aguda (AML) o síndrome mielodisplásico (MDS).
MX2016001087A 2013-07-26 2014-07-24 Volasertib en combinacion con azacitidina para el tratamiento de leucemia mieloide aguda y sindrome mielodisplasico. MX2016001087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361858804P 2013-07-26 2013-07-26
PCT/EP2014/065938 WO2015011235A1 (en) 2013-07-26 2014-07-24 Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii

Publications (1)

Publication Number Publication Date
MX2016001087A true MX2016001087A (es) 2016-04-20

Family

ID=51228430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001087A MX2016001087A (es) 2013-07-26 2014-07-24 Volasertib en combinacion con azacitidina para el tratamiento de leucemia mieloide aguda y sindrome mielodisplasico.

Country Status (12)

Country Link
US (3) US20150031643A1 (es)
EP (1) EP3024488A1 (es)
JP (1) JP2016525531A (es)
KR (1) KR20160035067A (es)
CN (1) CN105407923A (es)
AU (1) AU2014295019A1 (es)
CA (1) CA2919296A1 (es)
CL (1) CL2016000025A1 (es)
EA (1) EA201600134A1 (es)
MX (1) MX2016001087A (es)
PH (1) PH12016500083A1 (es)
WO (1) WO2015011235A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535112A (ja) * 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
WO2019145410A1 (en) * 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US8980850B2 (en) * 2011-11-03 2015-03-17 Millennium Pharmaceuticals, Inc. Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent

Also Published As

Publication number Publication date
JP2016525531A (ja) 2016-08-25
US20150031643A1 (en) 2015-01-29
EP3024488A1 (en) 2016-06-01
CA2919296A1 (en) 2015-01-29
CL2016000025A1 (es) 2016-09-30
US20170157158A1 (en) 2017-06-08
AU2014295019A1 (en) 2015-12-17
PH12016500083A1 (en) 2016-04-18
WO2015011235A1 (en) 2015-01-29
KR20160035067A (ko) 2016-03-30
US20190240242A1 (en) 2019-08-08
EA201600134A1 (ru) 2016-07-29
CN105407923A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
IL244888B (en) A pharmaceutical product containing mdm2-p53 binding inhibitor and cytrebine for the treatment of acute myeloid leukemia
PH12019502477A1 (en) Use of anti cd70 antibody argx-10 treat acute myeloid leukemia
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
IL242881B (en) A toxic substance for use in combination with radiation in cancer treatment
LT3033086T (lt) Kombinuota terapija vėžiui gydyti
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
NZ710392A (en) Cdc7 inhibitors
PH12016501099A1 (en) Materials and methods for controlling infections
IL234709B (en) A preparation for the treatment of acute myeloid leukemia
PL2984184T3 (pl) Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworu
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
IL240924B (en) Antagonistic peptide to cxcr4 and cytarabine for the treatment of myeloid leukemia
IN2012DN02195A (es)
PH12016500059A1 (en) Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome
PH12016500083A1 (en) Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
IS2934B (is) Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
AR098670A1 (es) Inhibidor de sglt1
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
WO2014180882A3 (en) Treatment of brain metastasis from cancer
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.